Complement activation, immunogenicity, and immune suppression as potential side effects of liposomes

Handbook of Harnessing Biomaterials in Nanomedicine

Volumn , Issue , 2012, Pages 309-334

  Szebeni, Janos ^a,c   Barenholz, Yechezkel Chezy ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSITY OF MISKOLC   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84881799557     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4032/9789814364270     Document Type: Chapter

References (93)

1. Alberts, D. S., Liu, P. Y., Wilczynski, S. R., Clouser, M. C., Lopez, M. A., Michelin, D. R, Lanzotti, V. J., and Markman, M. (2008).
2. Altina, J. G., and Parish, C. R. (2006). Liposomal vaccines - targeting the delivery of antigen. Methods 40, pp. 39-52.
3. Alving, C. R. (1991). Liposomes as carriers of antigens and adjuvants.J Immunol. Methods 140, pp. 1-13.
4. Alving, C. R., Kinsky, S. C, Haxby, J. A., and Kinsky, C. B. (1969). Antibody binding and complement fixation by a liposomal model membrane. Biochemistry 8, pp. 1582-1587.
5. Alving, C. R., Koulchin, V., Glenn, G. M., and Rao, M. (1995). Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol. Rev. 145, pp. 5-31.
6. Alving, C. R., and Swartz, G. M. (1991). Antibodies to cholesterol, cholesterol conjugates, and liposomes: implications for atherosclerosis and autoimmunity Crít. Rev. Immunol. 10, pp. 441-453.
7. Alving, C. R., Swartz, G. M. J., Wassef, N. M., Ribas, J. L., Herderick, E. E., Virmani, R., Kolodgie, F. D., Matyas, G. R., and Cornhill, J. F. (1996). Immunization with cholesterol-rich liposomes induces anti-cholesterol antibodies and reduces diet-induced hypercholesterolemia and plaque formation.J. Lab. Clin. Med. 127, pp. 40-49.
8. Alving, C. R., Urban, K. A., and Richards, R. L. (1980). Influence of temperatureoncomplement-dependent immune damage to liposomes. Biochim. Biophys. Acta 600, pp. 117-125.
9. Bangham, A. D. (1993). Liposomes: the Babraham connection. Chem. Phys. Lipids 64, pp. 275-285.
10. Bangham, A. D., and Horne, R. W. (1964). Negative staining of phospholipids and their structural modification by surface active agents as observed in the electron microscope.J. Mol. Biol. 8, pp. 660-668.
11. Barenholz, Y. (2006). Amphipathic weak base loading into preformed liposomes havingatransmembraneammoniumiongradient: fromthe benchto approved DOXIL, In Liposome Technology Vol2 [G. Gregoriadis, ed.], pp. 1-26. Informa Healthcare, New York, NY
12. Belchetz, P. E., Crawley, J. C, Braidman, I. R, and Gregoriadis, G. (1977). Treatment of Gaucher's disease with liposome-entrapped glucocerebroside: beta-glucosidase. Lancet 8029, pp. 116-117.
13. Bergers, J.J., Otter, W. D., and Crommelin, J. A. (1996). Liposome-based câncer vaccines.J. Liposome Res. 6, pp. 339-355.
14. Bonte, E., and Juliano, R. L. (1986). Interactions of liposomes with serum proteins. Chem. Phys. Lipids 40, pp. 359-372.
15. Cabriales, S., Bresnahan,J., Testa, D., Espina, B. M., Scadden, D. T., Ross, M., and Gill, R. S. (1998). Extravasation of liposomal daunorubicin in patients with AIDS-associated Kaposfs sarcoma: a report of four cases Oncol. Nurs. Forum 25, pp. 67-70.
16. Chanan-Khan, A., Szebeni,J., Savay, S., Liebes, L., Rafique, N. M., Alving, C. R., and Muggia, F. M. (2003). Complement activation following first exposure to pegylated liposomal doxorubicin [Doxil]: possible role in hypersensitivity reactions.Ann. Oncol. 14, pp. 1430-1437.
17. Chonn, A., Cullis, P. R., and Devine, D. V. (1991). The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes.J. lmmunol. 146, pp. 4234-4241.
18. Chopra, R., Blair, S., Strang,J., Cervi, R., Patterson, K. G., and Goldstone, A. H. (1991). Liposomal amphotericin B [AmBisome] in the treatment of fungai infections in neutropenic patients.J. Antimicrob. Chemother. 28 Suppl B, pp. 93-104.
19. Ciftcioglu, N., McKay D. S., Mathew, G., and Kajander, E. O. (2006). Nanobacteria: fact or fiction? Characteristics, detection, and medicai importance of novel self-replicating, calcifying nanoparticles. J. Investig. Med. 54, pp. 385-394.
20. Cunningham, C. M., Kingzette, M., Richards, R. L., Alving, C. R., Lint, T E, and Gewurz,H. (1979). Activation of human complement by liposomes: a model for membrane activation of the alternative pathway.J. lmmunol. 122, pp. 1237-1242.
21. Danenberg, H. D., Golomb, G., Groothuis, A., Gao, J., Epstein, H., Swaminathan, R. V. R., Seifert, R., and Edelman, E. R. (2003). Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits. Circulation 108, pp. 2798-2804.
22. de Marie, S. (1996). Liposomal and lipid-based formulations of amphotericin B. Leukemia 10, Suppl. 2., pp. S93-S96.
23. Deamer, D. (2009). On the origin of systems. Systems biology, synthetic biology and the origin of life. EMBO Rep. 10, Suppl 1, pp. Sl-4.
24. Deamer, D. W. (2008). Origins of life: how leaky were primitive cells? Nature 454 [7200], pp. 37-38.
25. Deamer, D. W. (2010). From "banghasomes" to liposomes: a memoir of Alec Bangham, 1921-2010. FASEB J. 24, pp. 1308-1310.
26. Diminsky, D., Moav, N., Gorecki, M., and Barenholz, Y. (1999). Physical, chemical and immunological stability of CHO derived hepatitis B surface antigen [HBsAg] particles. Vaccine 18, pp. 3-17.
27. Diminsky, D., Schirmbeck, R., Reimann,J., and Barenholz, Y. (1997). Comparison between hepatitis B surface antigen [HBsAg] particles derived from mammalian cells [CHO] and yeast cells [Hansenula polymorpha]: composition, structure and immunogenicity. Vaccine 15, pp. 637-647.
28. Doxil. (2010). Package insert. www.Doxil.com 2010 November.
29. Dujmovic, I. H. (2005). Comparison of two guidelines on immunotoxicology testing of medicinal products. Arh. Hig. Rada. Toksikol. 56, pp. 265-268.
30. Eckardt, J. R., Campbell, E., Burris, H. A., Weiss, G. R., Rodriguez, G. I., Fields, S. M., Thurman, A. M., Peacock, N. W., Cobb, R, Rothenberg, M. L., et al. (1994). A phase II trial of DaunoXome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the cólon. Am.J. Clin. Oncol. 17, pp. 498-501.
31. EMEA [2000]. Note for guidance on repeated dose toxicity. CPMP/SWP/1042/99.
32. Fossa, S. D., Aass, N., and Paro, G. (1998). A phase II study of DaunoXome in advanced urothelial transitional cell carcinoma. Eur. J. Cancer 34, pp. 1131-1132.
33. Funato,K., Yoda, R., and Kiwada, H. (1992). Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma. Biochim. Biophys. Acta 1103, pp. 198-204.
34. Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., and Barenholz, Y. (1994). Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54, pp. 987-992.
35. Gabizon, A., Isacson, R., Rosengarten, O., Tzemach, D., Shmeeda, H., and Sapir, R. (2007). An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemother. Pharmacol. 61, pp. 695-702.
36. Gabizon, A., Shmeeda, H., and Barenholz, Y. (2003). Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 42, pp. 419-436.
37. Gabizon, A., Tzemach, D., Mak, L., Bronstein, M., and Horowitz, A. T. (2002).Dosedependencyofpharmacokineticsandtherapeuticefficacy of pegylated liposomal Doxorubicin (DOXIL] in murine models.J. Drug Targeting 10, pp. 539-548.
38. Gill, P. S., Espina, B. M., Muggia, F, Cabriales, S., Tulpule, A., Esplin, J. A., Liebman, H. A., Forssen, E., Ross, M. E., and Levine, A. M. (1995). Phase I/II clinicai and pharmacokinetic evaluation of liposomal daunorubicin. J. Clin. Oncol. 13, pp. 996-1003.
39. Gill, R. S., Wernz, J., Scadden, D. T., Cohen, R., Mukwaya, G. M., von Roenn, J. H., Jacobs, M., Kempin, S., Silverberg, I., Gonzales, G., Rarick, M. U., Myers, A. M., Shepherd, E., Sawka, C., Pike, M. C., and Ross, M. E. (1996). Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.J. Clin. Oncol. 14, pp. 2353-2364.
40. Girard, R. M., Bouchaud, O., Goetschel, A., Mukwaya, G., Eestermans, G., Ross, M., Rozenbaum, W., and Saimot, A. G. (1996). Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma. AIDS 10, pp. 753-757.
41. Guaglianone, R., Chan, K., DelaFlor-Weiss, E., Hanisch, R., Jeffers, S., Sharma, D., and Muggia, F. (1994). Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome]. Invest. New Drugs 12, pp. 103-110.
42. Hamad, I., Al-Hanbali, O., Hunter, A. C., Rutt , K. J., Andresen, T. L., and Moghimi, S. M. (2010). Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering ACS Nano 4, pp. 6629-6638.
43. Harashima, H., Sakata, K., Funato, K., and Kiwada, H. (1994). Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm. Res. 11, pp. 402-406.
44. Harris, C. L., and Morgan, B. R. (2004). The many faces of the membrane regulators of complement, In The Complement System: Novel Roles in Health and Disease (J. Szebeni, ed.]. Kluwer, Boston.
45. Hashimoto, Y., Sugawara, M., and Endoh, H. (1983). Coating of liposomes with subunits of monoclonal IgM antibody and targeting of the liposomes.J. Immunol. Methods 62, pp. 155-162.
46. Hastings, K. L. (2002). Implications of the new FDA/CDER immunotoxicology guidance for drugs. Int. Immunopharmacol. 11, pp. 1613-1618.
47. Haxby, J. A., Gotze, O., Muller-Eberhard, H.J., and Kinsky, S. C. (1969). Release of trapped marker from liposomes by the action of purified complement components. Proc. Natl. Acad. Sci. U.S.A. 64, pp. 290-295.
48. Haxby, J. A., Kinsky, C. B., and Kinsky, S. C. (1968). Immune response of a liposomal model membrane. Proc. Natl. Acad. Sci. U.S.A. 61, pp. 300-307.
49. Ishida, T., Harada, M., Wang, X. Y., Ichihara, M., Irimura, K., and Kiwada, H. (2005). Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes.J. Control. Release 105, pp. 305-317.
50. Ishida, T., Ichihara, M., Wang, X., and Kiwada, H. (2006). Spleen plays an important role in the induetion of accelerated blood clearance of PEGylated liposomes.J. Control. Release 115, pp. 243-250.
51. Ishida, T., Ichihara, M., Wang, X., Yamamoto, K., Kimura, J., Majima, E., and Kiwada, H. (2006). Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes.J. Control. Release 112, pp. 15-25.
52. Ishida, T., Ichikawa, T., Ichihara, M., Sadzuka, Y., and Kiwada, H. (2004). Effect ofthe physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice./Control. Release 95, pp. 403-412.
53. Ishida, T., Maeda, R., Ichihara, M., Irimura, K., and Kiwada, H. (2003). Accelerated clearance of PEGylated liposomes in rats after repeated injections./Control. Release 88, pp. 35-42.
54. Ishida, T., Masuda, K., Ichikawa, T, Ichihara, M., Irimura, K., and Kiwada, H. (2003). Accelerated clearance of a second injection of PEGylated liposomes in mice. Int.]. Pharm. 255, pp. 167-174.
55. Ishihara, T.,Takeda, M.,Sakamoto, H.,Kimoto, A.,Kobayashi, C.,Takasaki, N., Yuki, K., Tanaka, K., Takenaga, M., Igarashi, R., Maeda, T., Yamakawa, N., Okamoto, Y., Otsuka, M., Ishida, T., Kiwada, H., Mizushima, Y., and Mizushima, T. (2009). Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm. Res. 10, pp. 2270-2279.
56. Kinsky, S. C., Haxby, J. A., Zopf, D. A., Alving, C. R, and Kinsky, C. B. (1969). Complement-dependent damage to liposomes prepared from purê lipids and Forssman hapten. Biochemistry 8, pp. 4149-4158.
57. Knol, E. E., Mui, F. R., Lie, W.J., Verhoeven, A.J., and Roos, D. (1996). The role of basophils in allergic disease. Eur. Respir.J. Suppl. 22, pp. 126s.
58. Koide, H., Asai, T., Hatanaka, K., Akai S., Ishii T., Kenjo, E., Ishida, T., Kiwada, H., Tsukada, H., and Oku, N. (2010). T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes. Int.]. Pharm. 392, pp. 218-223.
59. Koide, H.,Asai, T., Hatanaka, K., Urakami, T., Ishii, T., Kenjo, E., Nishihara, M., Yokoyama, M., Ishida, T., Kiwada, H., and Oku, N. (2008). Particle size-dependenttriggering of accelerated blood clearance phenomenon. Int. ]. Pharm. 362, pp. 197-200.
60. Lieberman, P. (1989). The use of antihistamines in the prevention and treatment of anaphylaxis and anaphylactoid reactions. Singapore Med. J. 30, pp. 290-293.
61. Lieberman, R. (1991). Anaphylactoid reactions to radiocontrast material. Clin. Rev. Allergy 9, pp. 319-338.
62. Lipinski, C. A., Lombardo, E., Dominy, B. W., and Feeney, R. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv. Rev. 23, pp. 3-25.
63. Marcato, R. D.,and Duran, N. (2008). Newaspects ofnanopharmaceutical delivery systems.J Nanoscience Nanotechnol. 8, pp. 1-14.
64. Masaki, T., Okada, N., Yasuda, R., and Okada, H. (1989). Assay of complement activity in human serum using large unilamellar liposomes.J. Immunol. Methods 123, pp. 19-24
65. Matyas, G. R., Wassef, N. M., Rao, M., and Alving, C. R. (2000). Induction and detection of antibodies to squalene.J Immunol. Methods 245, pp. 1-14.
66. Meunier, E., Prentice, H. G., and Ringdén, O. (1991). Liposomal amphotericin B [AmBisome]: safety data from a phase II/III clinicai trial.y. Antimicrob. Chemother. 28 Suppl B, pp. 83-91.
67. Moghimi, S. M., Andersen, A.J., Hashem, S. H., Lettiero, B., Ahmadvand, D., Hunter, A. C, Andresen, T. L., Hamad, I., and Szebeni, J. (2010). Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead.J. Control Release 146, pp. 175-181.
68. Moghimi, S. M., Hamad, I., Andresen, T. L., Jõrgensen, K., and Szebeni, J. (2006). Methylation of the phosphate oxygen moiety of phospholipid-methoxy[polyethylene glycol] conjugate prevenis PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J. 20, pp. 2591-2593.
69. Mold, C., and Gewurz, H. (1980). Activation of human complement by liposomes: serum factor requirement for alternative pathway activation.J Immunol. 125, pp. 696-700.
70. Money-Kyrle, J. E., Bates, E, Ready, J., Gazzard, B. G., Phillips, R. H., and Boag, E. C. (1993). Liposomal daunorubicin in advanced Kaposfs sarcoma: a phase II study Clin. Oncol. [R. Coll. Radiol.) 5, pp. 367-371.
71. Okada, N., Yasuda, T., Tsumita, T., and Okada, H. (1983). Membrane sialoglycolipids regulate the activation of alternative complement pathway by liposomes containing trinitrophenylaminocaproyldipalmitoylphosphatidylethaolamine. Immunology 48, pp. 129-140.
72. Ozato, K., Ziegler, H. K., and Henney, C. S. (1978). Liposomes as model membrane systems for immune attack. II. The interaction of complement and K cell populations with immobilized liposomes. J Immunol. 121, pp. 1383-1388.
73. Pedersen, M. B., Zhou, X., Larsen, E. K. U., Sorensen, U. S., Kjems, J., Nygaard, J. V., Nyengaard, J. R., Meyer, R. L., Boesen, T., and Vorup-Jensen, T. (2010). Curvature of synthetic and natural surfaces is an important target feature in classical pathway complement activation. J. Immunol. 184, pp. 1931-1945.
74. Richards, R. L., Habbersett, R. C., Scher, I., Janoff, A. S., Schieren, H. R., Mayer, L. D., Cullis, R. R.,and Alving, C. R. (1986). Influence ofvesicle size on complement-dependent immune damage to liposomes. Biochim. Biophys. Acta 855, pp. 223-230.
75. Richardson, D. S., Kelsey, S. M., Johnson, S. A., Tighe, M., Cavenagh, J. D., and Newland, A. C. (1997). Early evaluation of liposomal daunorubicin [DaunoXome, Nexstar] in the treatment of relapsed and refractory lymphoma. Invest. New Drugs 15, pp. 247-253.
76. Sculier, J. R., Coune, A., Brassinne, C., Laduron, C., Atassi, G., Ruysschaert, J. M., and Fruhling, J. (1986). Intravenous infusion of high doses of liposomes containing NSC 251635, a water-insoluble cytostatic agent. A pilot study with pharmacokinetic data.J Clin. Oncol. 4, pp. 789-797.
77. Solomon, R., and Gabizon, A. (2008). Clinicai pharmacology of liposomal anthracyclines: Focus on pegylated liposomal doxorubicin. Clin. Lymphoma Myeloma 8, pp. 21-32.
78. Sou, K., and Tsuchida, E. (2008). Electrostatic interactions and complement activation on the surface of phospholipid vesicle containingacidiclipids:effect of the structure of acidic groups. Biochim. Biophys. Acta 1778, pp. 1035-1041.
79. Storm, G., ten Kate, M. T., Working, P. K., and Bakker-Woudenberg, A. (1998). Doxorubicin entrapped in sterically stabilized liposomes: effects on bacterial blood clearance capacity of the mononuclear phagocyte system. Clin. Câncer Res. 4, pp. 111-115.
80. Szebeni, J. (1998). The interaction of liposomes with the complement system. Crit. Rev. Ther. Drug CarrierSyst. 15, pp. 57-88.
81. Szebeni, J. (2001). Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs and radiocontrast agents. Crit. Rev. Ther. Drug Carr. Syst. 18, pp. 567-606.
82. Szebeni, J. (2004). Complement activation-related pseudoallergy: mechanism of anaphylactoid reactions to drug carriers and radiocontrast agents, In The Complement System: Novel Roles in Health and Disease [J. Szebeni, ed.], pp. 399-440. Kluwer, Boston.
83. Szebeni, J. Baranyi, L. Savay, S. Milosevits, J. Bodo, M. Bunger, R. Alving, C.R. The interaction of liposomes with the complement system: in vitro and in vivo assays. Methods Enzymol. 373, pp. 136-154.
84. Szebeni, J. (2005). Complementactivation-related pseudoallergy: a new class of drug-induced immune toxicity. Toxicology 216, pp. 106-121.
85. Szebeni,J., Baranyi, B., Savay, S., Bodo, M., Morse, D. S., Basta, M., Stahl, G. L., Bunger, R., and Alving, C. R. (2000). Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction.Am. J. Physiol. 279, pp. H1319-H1328.
86. Szebeni, J., Baranyi, L., Sávay, S., Bodo, M., Milosevits, J.,Alving, C. R.,and Bünger, R. (2006). Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECGand heartfunction.Am. J. Physiol. 290, pp. H1050-H1058.
87. Szebeni,J., Bedõcs, R, Rozsnyay, Z., Weiszhár, Z., Rosivall, L., Cohen, R., Garbuzenko, O., Báthori, G., Tóth, M., Bünger, R., and Barenholz, Y. (2011). Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and Ambisome. Nanomed. Nanotechnol. Biol. Med. In press.
88. Szebeni, J., Bunger, R., Baranyi, L., Bedocs, R., Toth, M., Rosivall, L., Barenholz, Y., and Alving, C. R. (2007). Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles.J Liposome Res. 17, pp. 107-117.
89. Szebeni, J., Fontana, J. L., Wassef, N. M., Mongan, P. D., Morse, D. S., Dobbins, D. E., Stahl, G. L., Bünger, R., and Alving, C. R. (1999). Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudo-allergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CRI and anti- C5a antibody. Circulation 99, pp. 2302-2309.
90. Szebeni, J., Wassef, N. M., Hartman, K. R., Rudolph, A. S., and Alving, C. R (1997). Complement activation in vitro by the red blood cell substitute, liposome-encapsulated hemoglobin: Mechanism of activation and inhibition by soluble complement receptor type 1. Transfusion 37, pp. 150-159.
91. van de Wert, M., and Moller, E. H. (2008). Immunogenicity of biopharmaceuticals: causes, methods to reduce immunogenicity, and biosimilars, In Immunogenicity of Biopharmaceuticals?' (M. van de Wert and E. H. Moller, eds.), pp. 97-111. Springer, AAPS Press.
92. Venkatraman, S. S., Ma, L. L., Natarajan, J. V., and Chattopadhyay, S. (2010). Polymer- and liposome-based nanoparticles in targeted drug delivery. Front. Biosci. [Schol. Ed.] 2, pp. 801-814.
93. Wagner, V., Dullaart, A., Bock, A.-K., and Zweck, A. (2006). The emerging nanomedicine landscape. Nature Biotechnol. 24, pp. 1211-1217.